Issue

Vol. 63 No. 10: Issue 10

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Investigation of genotoxic effects of doripenem using cytogenetic and molecular methods

https://doi.org/10.14715/cmb/2017.63.10.14
M. Aydin
Departmant of Biology, Faculty of Science and Letters, Adiyaman University, Adiyaman, Turkey
http://orcid.org/0000-0002-1204-1163
E. Rencüzoğullari
Departmant of Biology, Faculty of Science and Letters, Adiyaman University, Adiyaman, Turkey
O. Bozkurt
Departmant of Biology, Natural and Applied Sciences Institute, Adiyaman University, Adiyaman, Turkey
A. Genç
Vocational School of Health Services, Adiyaman University, Adiyaman, Turkey
S. Bayram
Department of Nursing, Adiyaman School of Health, Adiyaman University, Adiyaman, Turkey

Corresponding Author(s) : E. Rencüzoğullari

erencuzogullari@adiyaman.edu.tr

Cellular and Molecular Biology, Vol. 63 No. 10: Issue 10

Abstract

The main aim of this study was to investigate the genotoxic effects of doripenem (DRP) using both cytogenetic and molecular test systems. Although there have been some studies reporting the effects of DRP, none of them has shown the genotoxic effects of DRP. In order to achieve the main aim of the study, the human peripheral lymphocytes were treated with 100 μg/ml, 200 μg/ml, and 400 μg/ml concentrations of DRP for 24 and 48 hours, and the chromosome aberration (CA) and micronucleus (MN) methods were used as the cytogenetic tests and RAPD-PCR method was used as the molecular test to determine the genotoxic effects of DRP. DRP did not induce the chromosome aberrations and micronucleus frequencies at all concentrations and at all treatment periods. So, it was concluded that DRP did not show any cytotoxic effect. However, DRP increased the number of polymorphic bands and decreased the ratio of genomic template stability, especially at the 48-hour treatment period. In this study, according to the obtained results, it was determined that DRP failed to show any genotoxic risk at the therapeutic doses. This result also indicates that DRP could be a reliable antibiotics according to its rapid metabolism.

Keywords

Chromosome aberration Micronucleus Genotoxicity RAPD-PCR Doripenem.
Aydin, M., Rencüzoğullari, E., Bozkurt, O., Genç, A., & Bayram, S. (2017). Investigation of genotoxic effects of doripenem using cytogenetic and molecular methods. Cellular and Molecular Biology, 63(10), 87–92. https://doi.org/10.14715/cmb/2017.63.10.14
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Capasso L. 5300 years ago, the Ice Man used natural laxatives and antibiotics. Lancet 1998; 352:1864.
  2. Cavallito CJ, Bailey JH. Allicin, the antibacterial principle of Allium sativum. I. Isolation, physical properties and antibacterial action. J Am Chem Soc 1944; 66:1950-1951.
  3. Goossens H, Ferech M, Stichele RV, Elseviers M. Outpatient antibiotic use in Europe and association with resistance. Lancet 2005; 365:579-87.
  4. WHO (World Health Organization). Global action plan on microbial resistance. http://www.wpro.who.int/entity/drug_resistance/resources/global_action_plan_eng.pdf (Last accessed: December 2016)
  5. Torres JA, Villegas MV, Quinn JP. Current concepts in antibiotic-resistant gram-negative bacteria.Expert Rev. Anti-Infect Ther 2007; 5:833-43.
  6. WHO (World Health Organization). Antimicrobial Resistance Global Report on Surveillance. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf (Last accessed December 2016)
  7. Iso Y, Irie T, Nishino Y, Motokawa K, Nishitani Y. A novel 1β-methylcarbapenem antibiotic, S-4661: Synthesis and structure-activity relationships of 2-(5 substituted pyrrolidin-3-ylthio)-1βmethylcarbapenems. J Antibiot (Tokyo) 1996; 49:199-209.
  8. Bradley JS, Garau J, Lode H, Rolston KV, Wilson SE, Quinn JP. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999; 11:93-100.
  9. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6:460-3.
  10. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
  11. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother 2005; 49:3944-7.
  12. Mandell L. Doripenem: a new carbapenem in the treatment of nosocomial infection,Clin Infect Dis 2009;49:1-3.
  13. Paterson DL, Depestel DD. Doripenem, Clin Infect Dis 2009; 49:291-8.
  14. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004; 48:3136-40.
  15. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report 2003. Clin Microbiol Infect 2005; 11:974-84.
  16. Merchant S, Gast C, Nathwani D, Lee M, Quintana A, Ketter N, Friedland I, Ingham M. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008; 30:717-33.
  17. Kongnakorn T, Mwamburi M, Merchant S, Akhras K, Caro JJ, Nathwani D. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation. Curr Med Res Opin 2010; 26:17-24.
  18. Gold HS, Pillai SK. Antistaphylococcal agents. Infect Dis Clin North Am 2009; 23:99-131.
  19. Jaju M, Jaju M, Ahuja YR. Evaluation of genotoxicity of ampicillin and carbenicillin on human lymphocytes in vitro: chromosome aberrations, mitotic index, cell cycle kinetics, satellite associations of acrocentric chromosomes and sister chromatid exchanges. Hum Toxicol 1984; 3:173-91.
  20. Rencuzogullari E, Ila HB, Topaktas M, Kayraldiz A, Budak S, Arslan M. No significant increase in chromosome aberrations and sister chromatid exchanges in cultured human lymphocytes treated with spiramycin. Teratogen Carcin Mut 2002; 22:51–8.
  21. Agarwal SK, Bhatnagar U, Rajesh N. Acute and genotoxic profile of a dimeric impurity of cefotaxime. Int J Toxicol 2004; 23:41-5.
  22. Venkatesh P, Shantala B, Jagetia GC, Rao KK, Baliga MS. Modulation of doxorubicin-induced genotoxicity by Aegle marmelos in mouse bone marrow: a micronucleus study. Integr Cancer Ther 2007; 6:42-53.
  23. Rencuzogullari E, Azirak S, Canimoglu S, Parlak S, Buyukleyla M. Effects of natamycin on sister chromatid exchanges, chromosome aberrations and micronucleus in human lymphocytes. Drug Chem Toxicol 2009; 32:47-52.
  24. Rocco L, Peluso C, Stingo V. Micronucleus test and comet assay for the evaluation of zebrafish genomic damage induced by erythromycin and lincomycin. Environ Toxicol 2012; 27:598-604.
  25. Cui J, Zhang Z, Ran Y, Zhao W, Kang X, Deng W. Study on the genotoxicity of cefuroxime lactone--an impurity substance in antibiotics. Wei Sheng Yan Jiu 2012; 41:717-22.
  26. Evans HJ. Handbook of Mutagenicity Test Procedures. In: Kilbey BJ, Legator M, Nichols W, Ramel C, eds., Human peripheral blood 63 lymphocytes for the analysis of chromosome aberrations in mutagen tests. 2nd ed. 1984; Amsterdam, Elsevier Science Publishers, Netherlands.
  27. Rencuzogullari E, Topaktas M. The relationship between quantities of bromodeoxyuridine and human peripheral blood with determination of the best differential staining of sister chromatids using chromosome medium-B. J Nat Appl Sci Ins 1991; 5:19-24.
  28. Paz-y-Miño C, Bustamante G, Sánchez ME, Leone PE. Cytogenetic monitoring in a population occupationally exposed to pesticides in Ecuador. Environ Health Perspect 2002; 110:1077-80.
  29. Mace JML, Daskal Y, Wray W. Scanning-electron microscopy of chromosome aberration. Mutat Res 1978; 52:199–206.
  30. Buyukleyla M, Rencuzogullari E. The effects of thymol on sister chromatid exchange, chromosome aberration and micronucleus in human lymphocytes. Exotoxicol Environ Safety 2009; 72:943-47.
  31. Fenech M. The in vitro micronucleus technique. Mutat Res 2000; 455:81–95.
  32. Kirsch-Volders M, Sofuni T, Aardema M, Albertini S, Eastmond D, Fenech M, Ishidate M Jr., Kirchner S, Lorge E, Morita T, et al. Report from the in vitro micronucleus assay working group. Mutat Res 2003; 540:153-63.
  33. Atienzar FA, Jha AN. The random amplified polymorphic DNA (RAPD) assay and related techniques applied to genotoxicity and carcinogenesis studies: a critical review. Mutat Res 2006; 613:76-102.
  34. Atienzar FA, Conradi M, Evenden AJ, Jha AN, Depledge MH. Qualitative assesment of genotoxicity using random amplified polymorphic DNA: Comparison of genomic template stability with key fitness parameters in Daphnia magna exposed to benzo[a]pyrene. Environ Toxicol Chem 1999; 18:2275–82.
  35. Turpin R, Lejeune J. Human afflictions and chromosomal aberrations. 1969; Pergamon Press, Oxford.
  36. Yunis JJ. ed. New chromosomal syndromes. 1977; Academic Press, Orlando, FL.
  37. Wilkins LE, Brown JA, Wolf B. Psychomotor development in 65 home-reared children with cri-du-chat syndrome. J Pediatr 1980; 97:401-5.
  38. Kirsch-Volders M, Elhajouji A, Cundari E, Van Hummelen P. The in vitro micronucleus test: a multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutat Res 1997; 392:19-30.
  39. Norppa H, Falck GCM. What Do Human Micronuclei Contain? Mutagen 2003; 18: 221-233.
  40. Kocaman AY, Renczzogullari E, Topaktas M. In vitro investigation of the genotoxic and cytotoxic effects of thiacloprid in cultured human peripheral blood lymphocytes. Environ Toxicol 2014; 29:631-41.
  41. Buyukleyla M. Detection of genotoxic effects of food additive sodium metabisulfite using RAPD/PCR method. PhD, í‡ukurova University, Adana, Turkey, 2013.
  42. Madle S, Beek B, Nowak C. Zum Verständnis von Chromosomenmutationstests an Somazellen. (To Understand the Chromosome Mutations in Somatic Cells) In: Fahrig, R., ed. Mutationsforschung und Genetische Toxicologie (Mutation and Genetic Toxicology). Germany, Wissenschaftliche Buchgesellschaft, 1993.
  43. Keam SJ. Doripenem. A review of its use in the treatment of bacterial infections. Drugs 2008; 68:2021-2057.
  44. Zavarise G, Ghiazza G, Grillo G, Morino P, Mondavio M. Evaluation of the effect of cloxacillin on human lymphocyte chromosomes through the study of karyotypic changes and sister chromatid exchanges. Boll Soc Ital Biol Sper 1984; 60:2143-8.
  45. Koseoglu V, Kismet E, Soysal Y, Ulucan H, Dündaröz R, Imirzalioglu N, Gökçay E. Investigation of DNA damage in lymphocytes exposed to benzathine penicillin G Pediatr Int 2004;46:415-8.
  46. Istifli ES, Topaktaş M. Cytogenetic genotoxicity of amoxicillin. Environ Mol Mutagen 2010; 51:222-8.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 779 Download : 395

Most read articles by the same author(s)